US-based techbio NemaLife has announced that it has joined the International Probiotic Association.
The global charity brings together various stakeholders in the probiotic sector to promote the safe and efficacious use of probiotics for human health and wellbeing.
A major bottleneck for the development of novel probiotics is the lack of rapid preclinical testing solutions that can evaluate the health benefits of novel bacterial strains. NemaLife has developed an automated and scalable in vivo testing platform that combines the microscopic worm C. elegans, microfluidics, and artificial intelligence.
This industry-validated platform addresses the limitations of in vitro models (e.g., TIM-2) and offers an alternative to costly, time-consuming, and energy-inefficient rodent testing. NemaLife’s 3R-compatible platform also aligns with the US Senate approved FDA Modernisation Act 2.0 that mandates reduction of testing with mammals.
We are thrilled to join IPA, the premier organisation connecting industry, academia, and regulatory bodies in the probiotic sector
Marton Toth, Ph.D., Chief Business Officer at NemaLife, said: “We are thrilled to join IPA, the premier organisation connecting industry, academia, and regulatory bodies in the probiotic sector. NemaLife’s AI-assisted platform can establish the health benefits of new strains for different areas, such as obesity, gut health, muscle health, healthy ageing, and cognitive health, in a matter of weeks compared to mammalian studies.
Toth continued: “This compelling value proposition will radically transform probiotic development. Our membership of the IPA is a perfect conduit to engage with stakeholders in this sector and bring in a new industry standard for preclinical testing.”
George Paraskevakos, Executive Director, IPA, said: “IPA is recognised as the unified Global Voice of Probiotics” around the world, and we are delighted to work with and welcome NemaLife into our community. The diversity of microbial strains being discovered is bringing new challenges in the entire value chain of developing pro/postbiotic products. NemaLife’s novel technology can fill critical gaps in this value chain by offering rapid in vivo data to guide R&D decision-making. Our IPA members are always on the lookout for novel solutions, and NemaLife’s cruelty-free approach has the potential to become the new industry standard for preclinical testing.”
NemaLife’s innovative platform was unveiled 3rd November at the IPA Probiotics Research Centre during the Supply Side West show in Las Vegas. Dr Dhaval Patel, Director of Research and Innovation at NemaLife, will present this platform and how it can be used to help companies accelerate the discovery of beneficial bacteria to develop safe and efficacious probiotics.
